首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

2126373

膀胱癌診斷市場－策略分析與預測（2026-2035）

Bladder Cancer Diagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月06日 | 出版商:

Knowledge Sourcing Intelligence | 英文 171 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

膀胱癌診斷市場預計將從 2026 年的 42.6 億美元成長到 2035 年的 94.2 億美元，複合年成長率為 9.2%。

膀胱癌診斷市場正經歷重大變革，其驅動力在於向非侵入性檢測、精準腫瘤學和個人化醫療的模式轉移。這一市場演變的特點是，人們日益認知到早期檢測和準確的分子特徵分析對於改善患者預後、降低醫療成本以及實現個人化治療策略至關重要。包括次世代定序、液態生物檢體和人工智慧（AI）病理診斷在內的先進分子技術的融合，使得膀胱癌的檢測和監測更加快速、靈敏且更易於獲取。隨著人口老化、吸菸率上升以及職業性致癌性暴露導致膀胱癌發病率持續成長，全球醫療系統正在擴展其診斷能力。市場對尿液生物標記檢測、分子診斷和伴隨診斷的投資顯著增加，這使得膀胱癌診斷成為泌尿系統腫瘤學和精準醫療的關鍵組成部分。

市場促進因素

全球膀胱癌發生率的不斷上升是膀胱癌診斷市場的主要驅動力。日益加重的疾病負擔導致篩檢、早期診斷、復發監測和疾病監測等應用領域對診斷檢測的需求持續成長。醫療系統正在擴展其診斷能力，以支持早期發現和個人化治療策略。這種需求推動了對各種診斷方式產品的需求，並永續擴大了膀胱癌診斷的應用。非侵入性尿液診斷技術的日益普及，透過提高患者依從性，進一步加速了市場成長。非侵入性檢測透過減少患者不適和膀胱鏡檢查相關的操作風險，鼓勵患者參與篩檢和監測。醫療機構正在將尿液來源的生物標記納入診斷演算法，以改善早期發現和監測。診斷設備製造商正在擴展其尿液檢測產品組合，以滿足不斷成長的需求。精準腫瘤學和伴隨診斷的日益普及推動了對分子譜分析和基因組檢測的需求。精準醫療需要準確的分子特徵分析來確定治療策略，從而持續推動了對先進診斷技術的需求。醫療機構正在拓展分子檢測能力，以支持個人化治療策略。診斷設備製造商正在開發專門的分子和基因組檢測解決方案，以支持精準腫瘤學的應用。分子診斷和基因組分析技術的進步正在提高診斷準確性和臨床效用。新一代定序（NGS）、液態生物檢體和人工智慧病理診斷技術的持續創新正在提高檢測的靈敏度和特異性。這些進步正在推動這些技術在臨床實踐中更廣泛的應用，並改善患者的治療效果。

市場限制因素

先進分子診斷檢測的高成本限制了其在資源匱乏的醫療系統中的應用。先進技術所需的大量資金投入對小規模的醫療機構和發展中地區構成障礙。一些傳統尿液生物標記檢測的敏感度有限，降低了其臨床可靠性和應用率。某些生物標記的性能限制也為臨床應用帶來挑戰。新診斷產品嚴格的法規核准要求增加了製造商的研發時間和成本。新診斷產品嚴格的證據要求也構成了市場准入障礙。在某些市場，新興基因組檢測的保險報銷範圍有限，限制了病患的取得和使用。

對技術和模式的洞察

技術發展趨勢的特徵是分子診斷、液態生物檢體和人工智慧平台的重要性日益凸顯。膀胱鏡檢查因其診斷準確率高，仍是膀胱癌診斷和後續觀察的臨床黃金標準。由於對非侵入性檢測的需求不斷成長，基於尿液的診斷方法正在快速發展。組織病理學對於確診和腫瘤特徵分析仍然至關重要。分子診斷在基因組分析和精準醫療應用等領域持續擴展。診斷影像繼續為疾病分期和治療方案製定提供支援。片段分析表明，免疫組織化學仍然廣泛用於腫瘤特徵分析和生物標記評估。 FISH技術繼續支持染色體異常的檢測。基於PCR的檢測方法能夠達到高靈敏度的分子分析。由於基因組分析和個人化醫療的選擇不斷增加，NGS是成長最快的技術。 NMP22仍然是膀胱癌檢測中最常用的尿液生物標記之一。 UroVysion FISH技術已被臨床廣泛接受用於膀胱癌復發監測。鑑於膀胱癌的高復發率，復發監測是一項至關重要的應用。醫院是該技術的主要終端用戶，診斷檢查室和泌尿系統診所也不斷擴展其檢測能力。隨著人工智慧驅動的病理學和影像診斷技術不斷提高診斷準確性和工作流程效率，人工智慧的整合變得日益重要。

競爭格局與策略展望

競爭格局包括成熟的診斷和生命科學公司，以及專注於分子診斷、泌尿系統和精準腫瘤學的供應商。羅氏開發分子、組織學、伴隨診斷和病理學解決方案，以支持膀胱癌的精準診斷和治療選擇。雅培提供免疫檢測、臨床化學系統、分子診斷和生物標記檢測解決方案，以支持腫瘤診斷。丹納赫提供基因組學技術、分子診斷、檢查室自動化和精準醫療解決方案，用於癌症診斷。賽默飛世爾科技開發PCR檢測、定序平台、分子診斷和精準腫瘤學技術，以支持膀胱癌篩檢。安捷倫專注於用於腫瘤應用的病理學解決方案、免疫組織化學檢測、基因組學技術和伴隨診斷。凱傑開發分子診斷檢測、PCR技術、檢體製備系統和伴隨診斷，以支持精準腫瘤學。 Illumina是領先的NGS平台供應商，其平台可實現全面的基因組分析和生物標記發現。 Bio-Rad致力於開發用於腫瘤檢測的數位PCR系統、分子診斷、免疫檢測和檢查室品管解決方案。各公司都在透過在尿液生物標記、液態生物檢體和人工智慧平台方面的創新來擴展其產品系列。在伴隨診斷開發和精準腫瘤解決方案需求的推動下，診斷製造商、製藥公司和研究機構之間的策略合作日益增加。近期的一些重要進展包括：Guardant Health推出了用於固體癌的先進基因組分析應用並擴展了其液態生物檢體產品系列；Exact Sciences通過擴展精準癌症檢測能力來加強其分子腫瘤診斷產品線；羅氏推出了先進的伴隨診斷解決方案以支持精準腫瘤學；以及Illumina擴展了其用於全面腫瘤基因組分析的NGS應用。

簡明結論

膀胱癌診斷市場預計將持續成長，這主要得益於疾病負擔、技術創新以及精準醫療的整合。從侵入性手術轉向非侵入性、分子整合方法，標誌著泌尿系統學領域的根本性變革。儘管高成本、生物標記的敏感性以及監管要求等挑戰依然存在，但對技術、夥伴關係和臨床檢驗的策略性投資正為市場領導帶來持續的競爭優勢。長期市場前景依然樂觀，膀胱癌診斷將發展成為精準腫瘤學的關鍵組成部分，在全球醫療保健系統中支持早期檢測、復發監測、治療方案選擇以及改善患者預後。

本報告的主要益處：

深入分析：詳細分析涵蓋各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業。
競爭格局：我們將了解主要公司的策略部署，並確定最佳的市場進入方式。
市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
實用建議：我們支援制定策略決策，以開發新的收入來源。
適用於廣泛的使用者群體：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

你用它來做什麼？

產業和市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範和影響、新產品開發以及競爭影響。

分析範圍

歷史資料（2021-2024 年）、基準年（2025 年）和預測資料（2026-2035 年）
成長機會、挑戰、供應鏈前景、法規結構、顧客行為和趨勢分析。
競爭對手定位、策略和市場佔有率分析
營收成長率及預測分析：依業務板塊及地區（國家）分類
企業概況（策略、產品、財務資訊、關鍵趨勢等）

分析：按診斷方式
- 膀胱鏡檢查
- 尿液診斷
- 組織病理學
- 分子診斷
- 診斷影像
分析：按技術
- 免疫組織化學（IHC）
- 螢光原位雜合反應（FISH）
- 聚合酵素鏈鎖反應（PCR）
- 次世代定序（NGS）
- 免疫測量
分析：透過生物標記
- NMP22
- 膀胱腫瘤抗原（BTA）
- UroVysion FISH
- 基於細胞角質蛋白的生物標記物
- 其他生物標記
分析：透過臨床應用
- 篩檢
- 初步診斷
- 復發監測
- 治療方案
- 疾病監測

第9章全球膀胱癌診斷市場：細分市場分析

依產品
- 裝置
- 試劑和耗材
- 軟體
透過技術
- 免疫組織化學（IHC）
- 螢光原位雜合反應（FISH）
- 聚合酵素鏈鎖反應（PCR）
- 次世代定序（NGS）
- 免疫測量
- 其他技術
最終用戶
- 醫院
- 診斷檢查室
- 泌尿系統診所
- 學術研究機構

第10章：全球膀胱癌診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章全球膀胱癌診斷市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
韓國
印度
澳洲
巴西
墨西哥
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Danaher Corporation
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
QIAGEN NV
Illumina, Inc.
Bio-Rad Laboratories, Inc.
Sysmex Corporation
Leica Biosystems
bioMerieux
Siemens Healthineers AG
Guardant Health, Inc.
Exact Sciences Corporation
Fujifilm Holdings Corporation

第14章全球膀胱癌診斷市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009085

The Bladder Cancer Diagnostics Market is set to reach USD 9.42 billion in 2035, growing at a CAGR of 9.2 % from USD 4.26 billion in 2026.

The bladder cancer diagnostics market is undergoing significant transformation driven by the paradigm shift toward non-invasive testing, precision oncology, and personalized medicine. The market's evolution is characterized by the growing recognition that early detection and accurate molecular characterization are essential for improving patient outcomes, reducing healthcare costs, and enabling personalized treatment strategies. The convergence of advanced molecular technologies, including next-generation sequencing, liquid biopsy, and artificial intelligence-assisted pathology, is enabling faster, more sensitive, and increasingly accessible bladder cancer detection and monitoring. Healthcare systems worldwide are expanding diagnostic capabilities as bladder cancer incidence continues to rise due to aging populations, smoking prevalence, and occupational carcinogen exposure. The market is witnessing significant investment in urine-based biomarker assays, molecular diagnostics, and companion diagnostics, positioning bladder cancer diagnostics as a critical component of urological oncology and precision medicine.

Market Drivers

The increasing global incidence of bladder cancer represents the primary driver for the bladder cancer diagnostics market. Rising disease burden creates sustained demand for diagnostic testing across screening, initial diagnosis, recurrence monitoring, and disease surveillance applications. Healthcare systems are expanding diagnostic capacity to support early detection and personalized treatment strategies. This requirement strengthens demand for diagnostic products across all modalities, resulting in sustained growth in bladder cancer diagnostic utilization. The rising adoption of non-invasive urine-based diagnostic technologies is further accelerating market growth through improved patient compliance. Non-invasive testing reduces patient discomfort and procedural risks associated with cystoscopy, encouraging broader screening and surveillance participation. Healthcare providers are incorporating urine-based biomarkers into diagnostic algorithms to improve early detection and monitoring. Diagnostic manufacturers are expanding urine-based assay portfolios to capture growing demand. The growing implementation of precision oncology and companion diagnostics is driving demand for molecular profiling and genomic testing. Precision medicine requires accurate molecular characterization to guide therapeutic decisions, creating sustained demand for advanced diagnostic technologies. Healthcare providers are expanding molecular testing capabilities to support personalized treatment strategies. Diagnostic manufacturers are developing specialized molecular and genomic testing solutions to support precision oncology applications. Technological advancements in molecular diagnostics and genomic profiling are improving diagnostic accuracy and clinical utility. Continuous innovation in NGS, liquid biopsy, and AI-assisted pathology is enhancing detection sensitivity and specificity. These advancements support broader clinical adoption and improved patient outcomes.

Market Restraints

High costs associated with advanced molecular diagnostic testing limit adoption in resource-constrained healthcare systems. The significant financial investment required for advanced technologies creates barriers for smaller facilities and developing regions. Limited sensitivity of some conventional urine biomarker assays reduces clinical confidence and adoption. The performance limitations of certain biomarkers create challenges for clinical implementation. Stringent regulatory approval requirements for novel diagnostics increase development timelines and costs for manufacturers. The rigorous evidence requirements for new diagnostic products create barriers to market entry. Limited reimbursement for emerging genomic testing in certain markets restricts patient access and adoption.

Technology and Modality Insights

The technology landscape is characterized by the growing importance of molecular diagnostics, liquid biopsy, and AI-enabled platforms. Cystoscopy remains the clinical gold standard for bladder cancer diagnosis and surveillance because of its high diagnostic accuracy. Urine-based diagnostics are experiencing rapid growth owing to increasing demand for non-invasive testing. Histopathology remains essential for definitive diagnosis and tumor characterization. Molecular diagnostics are expanding for genomic profiling and precision medicine applications. Imaging diagnostics continue supporting disease staging and treatment planning. The segment analysis reveals that immunohistochemistry remains widely utilized for tumor characterization and biomarker assessment. FISH technology continues supporting chromosomal abnormality detection. PCR-based assays enable sensitive molecular analysis. NGS is the fastest-growing technology due to expanding genomic profiling and personalized treatment selection. NMP22 remains one of the most commonly utilized urinary biomarkers for bladder cancer detection. UroVysion FISH has gained widespread clinical acceptance for recurrence monitoring. Recurrence monitoring represents a critical application because of the high recurrence rates associated with bladder cancer. Hospitals represent the leading end-user segment, with diagnostic laboratories and specialty urology clinics expanding testing capabilities. The integration of AI is becoming increasingly important as AI-assisted pathology and imaging diagnostics improve diagnostic accuracy and workflow efficiency.

Competitive and Strategic Outlook

The competitive landscape features established diagnostics and life science companies alongside specialized molecular, urology, and precision oncology providers. Roche develops molecular diagnostics, tissue diagnostics, companion diagnostics, and pathology solutions supporting precision diagnosis and treatment selection in bladder cancer. Abbott provides immunoassays, clinical chemistry systems, molecular diagnostics, and biomarker testing solutions supporting oncology diagnostics. Danaher offers genomics technologies, molecular diagnostics, laboratory automation, and precision medicine solutions for cancer diagnostics. Thermo Fisher Scientific develops PCR assays, sequencing platforms, molecular diagnostics, and precision oncology technologies supporting bladder cancer testing. Agilent specializes in pathology solutions, immunohistochemistry assays, genomic technologies, and companion diagnostics for oncology applications. QIAGEN develops molecular diagnostic assays, PCR technologies, sample preparation systems, and companion diagnostics supporting precision oncology. Illumina is a leading provider of NGS platforms enabling comprehensive genomic profiling and biomarker discovery. Bio-Rad develops digital PCR systems, molecular diagnostics, immunoassays, and laboratory quality control solutions for oncology testing. Companies are pursuing product portfolio expansion through innovation in urine-based biomarkers, liquid biopsy, and AI-enabled platforms. Strategic collaborations between diagnostic manufacturers, pharmaceutical companies, and research institutions are increasing, driven by the need for companion diagnostic development and precision oncology solutions. Recent key developments include Guardant Health expanding its liquid biopsy portfolio with enhanced genomic profiling applications for solid tumors. Exact Sciences strengthened its molecular oncology diagnostics pipeline through expanded precision cancer testing capabilities. Roche introduced advanced companion diagnostic solutions supporting precision oncology. Illumina expanded NGS applications for comprehensive oncology genomic profiling.

Short Conclusion

The bladder cancer diagnostics market is positioned for sustained growth driven by the convergence of disease burden, technological innovation, and precision medicine. The transition from invasive procedures toward integrated non-invasive and molecular diagnostic approaches represents a fundamental shift in urological oncology. While challenges related to high costs, biomarker sensitivity, and regulatory requirements persist, strategic investments in technology, partnerships, and clinical validation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with bladder cancer diagnostics evolving into a critical component of precision oncology, supporting early detection, recurrence monitoring, treatment selection, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Global Bladder Cancer Diagnostics Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Disease Overview
3.3 Disease Evolution and Diagnostic Landscape
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Disease Prevalence Analysis
3.8 Diagnosed Patient Population Analysis
3.9 Bladder Cancer Diagnostic Testing Volume Analysis
3.10 Patient Diagnostic Pathway Analysis

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Technologies
6.2 Product Innovation
6.3 Urine-Based Molecular Diagnostics
6.4 Artificial Intelligence in Bladder Cancer Diagnostics
6.5 Liquid Biopsy Technologies
6.6 Biomarker Discovery
6.7 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Global Bladder Cancer Diagnostics Market Landscape Analysis

8.1 Analysis by Diagnostic Modality
- 8.1.1 Cystoscopy
- 8.1.2 Urine-Based Diagnostics
- 8.1.3 Histopathology
- 8.1.4 Molecular Diagnostics
- 8.1.5 Imaging Diagnostics
8.2 Analysis by Technology
- 8.2.1 Immunohistochemistry (IHC)
- 8.2.2 Fluorescence In Situ Hybridization (FISH)
- 8.2.3 Polymerase Chain Reaction (PCR)
- 8.2.4 Next-Generation Sequencing (NGS)
- 8.2.5 Immunoassays
8.3 Analysis by Biomarker
- 8.3.1 NMP22
- 8.3.2 Bladder Tumor Antigen (BTA)
- 8.3.3 UroVysion FISH
- 8.3.4 Cytokeratin-Based Biomarkers
- 8.3.5 Other Biomarkers
8.4 Analysis by Clinical Application
- 8.4.1 Screening
- 8.4.2 Initial Diagnosis
- 8.4.3 Recurrence Monitoring
- 8.4.4 Treatment Selection
- 8.4.5 Disease Surveillance

9. Global Bladder Cancer Diagnostics Market Segment Analysis (2021-2035)

9.1 By Product
- 9.1.1 Instruments
- 9.1.2 Reagents & Consumables
- 9.1.3 Software
9.2 By Technology
- 9.2.1 Immunohistochemistry (IHC)
- 9.2.2 Fluorescence In Situ Hybridization (FISH)
- 9.2.3 Polymerase Chain Reaction (PCR)
- 9.2.4 Next-Generation Sequencing (NGS)
- 9.2.5 Immunoassays
- 9.2.6 Other Technologies
9.3 By End User
- 9.3.1 Hospitals
- 9.3.2 Diagnostic Laboratories
- 9.3.3 Specialty Urology Clinics
- 9.3.4 Academic & Research Institutes

10. Global Bladder Cancer Diagnostics Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Global Bladder Cancer Diagnostics Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Japan
11.9 China
11.10 South Korea
11.11 India
11.12 Australia
11.13 Brazil
11.14 Mexico
11.15 Saudi Arabia
11.16 South Africa

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 F. Hoffmann-La Roche Ltd.
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 Abbott Laboratories
- 13.2.1 Company Overview
- 13.2.2 Financials
- 13.2.3 Product Portfolio
- 13.2.4 Recent Developments
13.3 Danaher Corporation
- 13.3.1 Company Overview
- 13.3.2 Financials
- 13.3.3 Product Portfolio
- 13.3.4 Recent Developments
13.4 Thermo Fisher Scientific Inc.
- 13.4.1 Company Overview
- 13.4.2 Financials
- 13.4.3 Product Portfolio
- 13.4.4 Recent Developments
13.5 Agilent Technologies, Inc.
- 13.5.1 Company Overview
- 13.5.2 Financials
- 13.5.3 Product Portfolio
- 13.5.4 Recent Developments
13.6 QIAGEN N.V.
- 13.6.1 Company Overview
- 13.6.2 Financials
- 13.6.3 Product Portfolio
- 13.6.4 Recent Developments
13.7 Illumina, Inc.
- 13.7.1 Company Overview
- 13.7.2 Financials
- 13.7.3 Product Portfolio
- 13.7.4 Recent Developments
13.8 Bio-Rad Laboratories, Inc.
- 13.8.1 Company Overview
- 13.8.2 Financials
- 13.8.3 Product Portfolio
- 13.8.4 Recent Developments
13.9 Sysmex Corporation
- 13.9.1 Company Overview
- 13.9.2 Financials
- 13.9.3 Product Portfolio
- 13.9.4 Recent Developments
13.10 Leica Biosystems
- 13.10.1 Company Overview
- 13.10.2 Financials
- 13.10.3 Product Portfolio
- 13.10.4 Recent Developments
13.11 bioMerieux
- 13.11.1 Company Overview
- 13.11.2 Financials
- 13.11.3 Product Portfolio
- 13.11.4 Recent Developments
13.12 Siemens Healthineers AG
- 13.12.1 Company Overview
- 13.12.2 Financials
- 13.12.3 Product Portfolio
- 13.12.4 Recent Developments
13.13 Guardant Health, Inc.
- 13.13.1 Company Overview
- 13.13.2 Financials
- 13.13.3 Product Portfolio
- 13.13.4 Recent Developments
13.14 Exact Sciences Corporation
- 13.14.1 Company Overview
- 13.14.2 Financials
- 13.14.3 Product Portfolio
- 13.14.4 Recent Developments
13.15 Fujifilm Holdings Corporation
- 13.15.1 Company Overview
- 13.15.2 Financials
- 13.15.3 Product Portfolio
- 13.15.4 Recent Developments